Cargando…

Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden

OBJECTIVES: Stat3 is persistently activated in ovarian cancer cells, with a crucial role in tumour onset and progression. In this study, we examined the anti‐tumour effect of a small‐molecule inhibitor napabucasin (BBI608) on epithelial ovarian cancer (EOC) in vitro and in vivo, and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongyi, Qian, Yanping, Wang, Xi, Pi, Ruyu, Zhao, Xia, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985655/
https://www.ncbi.nlm.nih.gov/pubmed/31778258
http://dx.doi.org/10.1111/cpr.12719
_version_ 1783491850845290496
author Li, Hongyi
Qian, Yanping
Wang, Xi
Pi, Ruyu
Zhao, Xia
Wei, Xiawei
author_facet Li, Hongyi
Qian, Yanping
Wang, Xi
Pi, Ruyu
Zhao, Xia
Wei, Xiawei
author_sort Li, Hongyi
collection PubMed
description OBJECTIVES: Stat3 is persistently activated in ovarian cancer cells, with a crucial role in tumour onset and progression. In this study, we examined the anti‐tumour effect of a small‐molecule inhibitor napabucasin (BBI608) on epithelial ovarian cancer (EOC) in vitro and in vivo, and investigated the underlying molecular mechanism of this drug in combination with paclitaxel. MATERIALS AND METHODS: A total of 156 ovarian cancer patient samples were analysed to determine the correlation between pStat3 expression in tumour cells and the prognosis of EOC patients. The anti‐tumour effect of BBI608 and/or paclitaxel on ovarian cancer in vitro was evaluated by CCK‐8, flow cytometry, Western blot and transwell assays. An in vivo intraperitoneal model was performed to confirm the effect of BBI608 on pStat3‐mediated peritoneal metastasis when combined with paclitaxel. RESULTS: Patients with high expression of pStat3 had poorer overall survival and progression‐free survival than those with low pStat3 expression. The synergy of BBI608 in combination with paclitaxel exerted dramatic growth inhibition and induced apoptosis in EOC cell lines. In vivo, the combination of two drugs significantly decreased intraperitoneal tumour burden and ascites volume, prolonged survival of tumour‐bearing mice compared with each monotherapy; these results were associated with downregulation of phospho‐Stat3 and activation of apoptosis pathway. CONCLUSIONS: Targeting the activation of Stat3 may be a potential therapeutic approach for EOC by acting synergistically with paclitaxel.
format Online
Article
Text
id pubmed-6985655
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69856552020-03-13 Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden Li, Hongyi Qian, Yanping Wang, Xi Pi, Ruyu Zhao, Xia Wei, Xiawei Cell Prolif Original Articles OBJECTIVES: Stat3 is persistently activated in ovarian cancer cells, with a crucial role in tumour onset and progression. In this study, we examined the anti‐tumour effect of a small‐molecule inhibitor napabucasin (BBI608) on epithelial ovarian cancer (EOC) in vitro and in vivo, and investigated the underlying molecular mechanism of this drug in combination with paclitaxel. MATERIALS AND METHODS: A total of 156 ovarian cancer patient samples were analysed to determine the correlation between pStat3 expression in tumour cells and the prognosis of EOC patients. The anti‐tumour effect of BBI608 and/or paclitaxel on ovarian cancer in vitro was evaluated by CCK‐8, flow cytometry, Western blot and transwell assays. An in vivo intraperitoneal model was performed to confirm the effect of BBI608 on pStat3‐mediated peritoneal metastasis when combined with paclitaxel. RESULTS: Patients with high expression of pStat3 had poorer overall survival and progression‐free survival than those with low pStat3 expression. The synergy of BBI608 in combination with paclitaxel exerted dramatic growth inhibition and induced apoptosis in EOC cell lines. In vivo, the combination of two drugs significantly decreased intraperitoneal tumour burden and ascites volume, prolonged survival of tumour‐bearing mice compared with each monotherapy; these results were associated with downregulation of phospho‐Stat3 and activation of apoptosis pathway. CONCLUSIONS: Targeting the activation of Stat3 may be a potential therapeutic approach for EOC by acting synergistically with paclitaxel. John Wiley and Sons Inc. 2019-11-28 /pmc/articles/PMC6985655/ /pubmed/31778258 http://dx.doi.org/10.1111/cpr.12719 Text en © 2019 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Li, Hongyi
Qian, Yanping
Wang, Xi
Pi, Ruyu
Zhao, Xia
Wei, Xiawei
Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title_full Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title_fullStr Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title_full_unstemmed Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title_short Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
title_sort targeted activation of stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985655/
https://www.ncbi.nlm.nih.gov/pubmed/31778258
http://dx.doi.org/10.1111/cpr.12719
work_keys_str_mv AT lihongyi targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden
AT qianyanping targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden
AT wangxi targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden
AT piruyu targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden
AT zhaoxia targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden
AT weixiawei targetedactivationofstat3incombinationwithpaclitaxelresultsinincreasedapoptosisinepithelialovariancancercellsandareducedtumourburden